GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: March 17, 2003, 16:34:47 ; Search time 39 Seconds
(without alignments)
888.337 Million cell updates/sec

Title: US-09-840-243B-11
Perfect score: 1341
Sequence: 1 MELTQPAEDLIQTQQTPASE.....VIENHILKLFQSNLVPADPE 260

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1341	100.0	260	21	AAY79411	Human MHC class II
2	1341	100.0	260	21	AAY59539	Human ankyrin fami
3	1113.5	83.0	269	21	AAY59590	Ankyrin repeat pro
4	625	46.6	229	23	ABP41881	Human ovarian anti
5	621.5	46.3	313	22	AAG66309	Human ankyrin-like
6	621.5	46.3	313	22	AAB94322	Human protein sequ
7	607.5	45.3	263	22	AAU20646	Human secreted pro
8	495	36.9	152	22	ABB50161	Human transcriptio
9	421.5	31.4	84	21	AAG01584	Human secreted pro
10	393	29.3	119	22	AAU20665	Human secreted pro
11	364	27.1	105	22	AAU20558	Human secreted pro
12	299	22.3	81	23	ABB97342	Novel human protei
13	274	20.4	234	22	ABB61859	Drosophila melanog
14	257	19.2	49	22	ABB43550	Peptide #11056 enc
15	257	19.2	49	22	AAM21225	Peptide #7659 enco
16	257	19.2	49	23	ABG46308	Human peptide enco
17	212	15.8	705	22	AAG75604	Human colon cancer
18	212	15.8	1762	23	AAU96841	Rat kidins220 prot
19	210.5	15.7	2443	22	ABB60521	Drosophila melanog
20	207.5	15.5	166	23	ABB78585	3 ankyrin repeat m
21	207.5	15.5	1715	22	AAM38993	Human polypeptide
22	207.5	15.5	1715	22	AAM39025	Human polypeptide
23	207.5	15.5	1715	23	AAU96840	Human kidins220 pr
24	206.5	15.4	1763	23	AAU80244	Rat kidins220 prot
25	205.5	15.3	342	22	ABB59641	Drosophila melanog
26	205	15.3	348	19	AAW70607	Ankyrin protein fr
27	205	15.3	348	19	AAW76775	D. immitis ankyrin
28	205	15.3	348	21	AAB11588	D. immitis ankyrin
29	205	15.3	348	23	AAO21367	Ankyrin protein se
30	205	15.3	1745	19	AAW70608	Full length ankyri
31	205	15.3	1745	19	AAW76776	D. immitis ankyrin
32	205	15.3	1745	21	AAB11589	D. immitis ankyrin
33	205	15.3	1745	23	AAO21368	Ankyrin protein se
34	204.5	15.2	978	21	AAB42288	Human ORFX ORF2052
35	202.5	15.1	765	22	AAB85514	Human protein kina
36	202.5	15.1	1872	22	AAM79160	Human protein SEQ
37	199	14.8	1498	22	ABB64857	Drosophila melanog
38	198	14.8	627	23	AAO17136	Human cancer cell
39	196.5	14.7	551	22	AAE01035	Human death domain
40	196	14.6	1377	22	ABG08072	Novel human diagno
41	195.5	14.6	456	21	AAG12893	Arabidopsis thalia
42	195.5	14.6	456	21	AAG27402	Arabidopsis thalia
43	195	14.5	435	22	AAG66710	Human cell growth
44	195	14.5	435	22	AAB93879	Human protein sequ
45	193	14.4	4274	22	ABG00972	Novel human diagno

ALIGNMENTS

RESULT 1
AAY79411
ID AAY79411 standard; Protein; 260 AA.
XX
AC AAY79411;
XX
DT 01-AUG-2000 (first entry)
XX
DE Human MHC class II gene transcription factor RFXANK.
XX
KW RFXANK; HsRFXANK; human; transcription factor; MHC class II;
KW chromosome 19p12; immunosuppressive; immunomodulator;
KW antiinflammatory; antidiabetic; antiarthritic; therapy;
KW inflammation; autoimmune diseases; transplant rejection;
KW insulin dependent diabetes; multiple sclerosis;
KW lupus erythematosus; rheumatoid arthritis; immunodeficiency.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Region 122..156
FT /note= "ankyrin repeat region 1"
FT Region 157..188
FT /note= "ankyrin repeat region 2"
FT Region 189..222
FT /note= "ankyrin repeat region 3"
XX
PN EP995798-A1.
XX
PD 26-APR-2000.
XX
PF 24-OCT-1998; 98EP-0120085.
XX

PR 24-OCT-1998; 98EP-0120085.
XX
PA (NOVI-) NOVIMMUNE SA.
XX
PI Masternak K, Reith W, Mach B;
XX
DR WPI; 2000-294958/26.
DR N-PSDB; AAZ94868.
XX
PT Novel isolated transcription factor, RFXANK, useful for treating MHC
PT class II deficiency and autoimmune disorders, e.g. insulin dependent
PT diabetes and multiple sclerosis, restores the functional transcription
PT of MHC class II genes -
XX
PS Claim 1; Fig 3; 48pp; English.
XX
CC The present sequence is that of human RFXANK, a novel transcription
CC factor that is a subunit of the RFX heterotrimeric transcription
CC complex that binds to the conserved X box motif of all MHC class II
CC gene promoters. The RFXANK gene is mutated in complementation group
CC B MHC II deficiency patients. Mutations identified in patients
CC include aberrant splicing and short deletions in exon 6. The
CC nvention provides inhibitors of RFXANK including antibodies, single
CC chain antibodies, dominant negative mutants, antisense molecules
CC and ribozymes. The inhibitors may be used in therapy or prevention
CC of diseases associated with aberrant expression of MHC class II
CC genes and/or as an immunosuppressive agents, e.g. to treat
CC inflammation, autoimmune diseases or rejection of transplanted
CC organs, insulin dependent diabetes, multiple sclerosis, lupus
CC erythematosus and rheumatoid arthritis. The compositions may also
CC be used to treat the autosomal recessive disease MHC class II
CC deficiency. Since RFXANK does not play any other major role in the
CC transcriptional control of genes other than MHC class II genes, its
CC inhibitors are devoid of other undesirable inhibitory effects.
XX
SQ Sequence 260 AA;

Query Match 100.0%; Score 1341; DB 21; Length 260;
Best Local Similarity 100.0%; Pred. No. 2e-128;
Matches 260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60

Qy      61 PQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELDQLKEHLRKGDNLVNKP 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 PQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELDQLKEHLRKGDNLVNKP 120

Qy     121 DERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERD 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 DERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERD 180

Qy     181 VDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQ 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQ 240

Qy     241 VIENHILKLFQSNLVPADPE 260
          ||||||||||||||||||||
Db     241 VIENHILKLFQSNLVPADPE 260
```

RESULT 2
AAY59539
ID AAY59539 standard; Protein; 260 AA.
XX
AC AAY59539;
XX
DT 03-APR-2000 (first entry)
XX
DE Human ankyrin family protein, ANFP.
XX
KW Human; ankyrin family protein; ANFP; autoimmune disorder; inflammation;
KW atherosclerosis; inflammatory disorder; proliferative disorder; AIDS;
KW vesicle-trafficking disorder; allergy; amyloidosis; anaemia; asthma;
KW bronchitis; Crohn's disease; atopic dermatitis; diabetes mellitus;
KW irritable bowel syndrome; osteoporosis; rheumatoid arthritis; cirrhosis;
KW hepatitis; ulcerative colitis; cancer; hypercholesterolaemia; therapy;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN US5989863-A.
XX
PD 23-NOV-1999.
XX
PF 14-OCT-1998; 98US-0172977.
XX
PR 14-OCT-1998; 98US-0172977.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Tang YT, Corley NC, Yue H, Guegler KJ;
XX
DR WPI; 2000-095634/08.
DR N-PSDB; AAZ49052.
XX
PT Polynucleotide sequence encoding a human ankyrin family protein useful
PT for diagnosis or treatment of autoimmune, inflammatory, proliferative
PT and vesicle-trafficking disorders -
XX
PS Claim 1; Fig 1; 34pp; English.
XX
CC This sequence is the human ankyrin family protein, ANFP, of the
CC invention. Host cells containing an expression vector containing the
CC polynucleotide sequence can be cultured to produce ANFP, which can be
CC used for diagnosis or treatment of autoimmune, inflammatory,
CC proliferative and vesicle-trafficking disorders. Disorders which can be
CC treated include acquired immune deficiency syndrome (AIDS), allergies,
CC amyloidosis, anaemia, asthma, atherosclerosis, bronchitis, Crohn's
CC disease, atopic dermatitis, diabetes mellitus, irritable bowel syndrome,
CC myocardial or pericardial inflammation, osteoporosis, rheumatoid
CC arthritis, cirrhosis, hepatitis, ulcerative colitis, cancer and
CC hypercholesterolaemia. The polynucleotide sequences can also be used as a
CC hybridisation probe to detect ANFP-encoding polynucleotides in biological
CC samples. Purified ANFP can be used to produce antibodies or to screen
CC libraries of pharmaceutical agents to find agents that specifically bind
CC ANFP. The DNA and its antisense sequence can be used in therapeutic
CC compositions e.g. to regulate gene function. The DNA sequence can be used
CC for diagnostic purposes to detect and quantitate gene expression in
CC biopsied tissues and to indicate the absence, presence and excess
CC expression of ANFP and monitor its levels during therapeutic
CC intervention.
XX
SQ Sequence 260 AA;

Query Match 100.0%; Score 1341; DB 21; Length 260;
Best Local Similarity 100.0%; Pred. No. 2e-128;
Matches 260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60

Qy      61 PQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELDQLKEHLRKGDNLVNKP 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 PQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELDQLKEHLRKGDNLVNKP 120

Qy     121 DERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERD 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 DERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERD 180

Qy     181 VDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQ 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQ 240
```

```
Qy     241 VIENHILKLFQSNLVPADPE 260
           ||||||||||||||||||||
Db     241 VIENHILKLFQSNLVPADPE 260
```

RESULT 3
AAY59590
ID   AAY59590 standard; Protein; 269 AA.
XX
AC   AAY59590;
XX
DT   03-APR-2000 (first entry)
XX
DE   Ankyrin repeat protein TVL-1.
XX
KW   Ankyrin repeat protein; TVL-1; TNF; tumour necrosis factor; apoptosis;
KW   cell cycle regulation; apoptotic cell death; cell proliferation.
XX
OS   Mus sp.
XX
PN   WO9967269-A1.
XX
PD   29-DEC-1999.
XX
PF   24-JUN-1999;   99WO-US14353.
XX
PR   24-JUN-1998;   98US-0090742.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Tsichlis PN, Makris A;
XX
DR   WPI; 2000-106276/09.
DR   N-PSDB; AAZ49069.
XX
PT   Novel isolated nucleic acid useful for biological screens to identify
PT   therapeutic agents involved in regulation of cell cycle progression and
PT   apoptotic cell death -
XX
PS   Claim 12; Fig 2C; 112pp; English.
XX
CC   This sequence is the ankyrin repeat protein, TVL-1 of the invention.
CC   The protein contains ankyrin repeat domains and is capable of promoting
CC   TNF (tumour necrosis factor) induced apoptosis. The nucleic acid
CC   molecules, proteins and antibodies are useful as targets for screening
CC   therapeutic agents that regulate cell cycle progression and apoptotic
CC   cell death, especially useful for identification, detection and/or
CC   regulation of complex signalling events that regulate cell cycle
CC   progression and apoptotic cell death. The Tvl-1 molecules of the
CC   invention can also be used as a research tool and will facilitate the
CC   elucidation of the mechanistic action of the novel genetic and protein
CC   interactions involved in the control of cellular proliferation and
CC   apoptosis.
XX
SQ   Sequence   269 AA;

Query Match 83.0%; Score 1113.5; DB 21; Length 269;
Best Local Similarity 81.9%; Pred. No. 3.6e-105;
Matches 221; Conservative 15; Mismatches 23; Indels 11; Gaps 2;

```
Qy       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60
           || || ||:|:  || |  :| |||| :|: : |||||||||||||: |||| ||| ||
Db       1 MEPTQVAENLVPNQQPPVPDLEDPEDTRDESPENSDTVVLSLFPCTPDAVNPEADASASS 60

Qy      61 PQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELDQLKEHLRK-------- 112
             | || |||||||||||||||||||||||||||||||||||| |||:||||
Db      61 LQ-GSFLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELSQLKDHLRKGACPACTC 119

Qy     113 --GDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYT 170
             |:||:|||||||||||||||||||||||:|||||||||||||||| ||||
Db     120 LSGNNLINKPDERGFTPLIWASAFGEIETVRFLLDWGADPHILAKERESALSLASMGGYT 179

Qy     171 DIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLA 230
```

```
           ||| |||:|||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     180 DIVRLLLDRDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLA 239

Qy     231 VALGYRKVQQVIENHILKLFQSNLVPADPE 260
           ||||||||||:|:|||:|||| | | |||
Db     240 VALGYRKVQQVMESHILRLFQSTLGPVDPE 269
```

RESULT 4
ABP41881
ID   ABP41881 standard; Protein; 229 AA.
XX
AC   ABP41881;
XX
DT   22-AUG-2002 (first entry)
XX
DE   Human ovarian antigen HWHKD22, SEQ ID NO:3013.
XX
KW   Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW   ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW   infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW   PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW   inflammatory condition; immune disorder; blood disorder;
KW   cardiovascular disorder; respiratory disorder; neurological disorder;
KW   gastrointestinal disorder; urinary system disorder; drug screening;
KW   gene therapy; chromosome mapping; forensic analysis;
KW   antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW   antiinflammatory; gynaecological; reproductive.
XX
OS   Homo sapiens.
XX
PN   WO200200677-A1.
XX
PD   03-JAN-2002.
XX
PF   07-JUN-2001; 2001WO-US18569.
XX
PR   07-JUN-2000; 2000US-209467P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE, Rosen CA;
XX
DR   WPI; 2002-147878/19.
DR   N-PSDB; ABQ54958.
XX
PT   Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT   useful in the prevention, treatment and diagnosis of cancer (e.g.
PT   ovarian cancer), immune disorders, cardiovascular disorders and
PT   neurological diseases -
XX
PS   Claim 11; SEQ ID No 3013; 2922pp; English.
XX
CC   The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC   ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC   encompasses polypeptides 90% identical and polynucleotides 95% identical
CC   to the sequences of the invention. The invention additionally relates to
CC   recombinant vectors and host cells comprising human ovarian antigen
CC   polynucleotides, antibodies against human ovarian antigens, and the use
CC   of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC   treating, prognosing or preventing various ovary and/or breast-related
CC   disorders. Such conditions include ovarian cancer and breast cancer, and
CC   metastatic tumours of ovarian or breast origin, reproductive system
CC   disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC   polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC   disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC   shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC   vaginitis), immune disorders (e.g., congenital and acquired
CC   immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC   blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC   respiratory disorders, neurological disorders, gastrointestinal disorders
CC   and urinary system disorders. Ovarian antigen polypeptides and
CC   polynucleotides may also be used in screening for compounds which

```
CC   modulate ovarian antigen expression or activity. The polynucleotides may
CC   further be used for gene therapy, chromosome mapping, in the
CC   identification of individuals and in forensic analysis, and the
CC   polypeptides may be used as food additives or to prepare antibodies
CC   useful in disease diagnosis, drug targeting and phenotyping. The present
CC   sequence represents a human ovarian antigen of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   229 AA;

  Query Match             46.6%;  Score 625;  DB 23;  Length 229;
  Best Local Similarity   58.6%;  Pred. No. 2.2e-55;
  Matches  130;  Conservative   26;  Mismatches   58;  Indels    8;  Gaps    3;

Qy      37 TVVLSLFPCTPEPVNPEPDASV------SSPQAGSSLKHSTTLTNRQRGNEVSALPATLD 90
           | |  |  |     :| |    |       |: :  | :| ||||||: ||||||  |   :
Db       7 TFVFHLAECNIH-TSPSPGIQVRHVYTPSTTKHFSPIKQSTTLTNKHRGNEVSTTPLLAN 65

Qy      91 SLSIHQLAAQGELDQLKEHLRKGDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADP 150
           |||:||||||||:  |    : : :|::|   || |||||:||:| |:|   | |||: ||||
Db      66 SLSVHQLAAQGEMLYLATRIEQ-ENVINHTDEEGFTPLMWAAAHGQIAVVEFLLQNGADP 124

Qy     151 HILAKERESALSLASTGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALL 210
            :| | |||||||| : |||||| :||:  ||:| |||||||||||| |||||||: ||
Db     125 QLLGKGRESALSLACSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLL 184

Qy     211 ARGADLTTEADSGYTPMDLAVALGYRKVQQVIENHILKLFQS 252
           |||  |  | ||||  |||||||||| |||||||:|:||| |:
Db     185 ESGADPTIETDSGYNSMDLAVALGYRSVQQVIESHLLKLLQN 226


RESULT 5
AAG66309
ID   AAG66309 standard; Protein; 313 AA.
XX
AC   AAG66309;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Human ankyrin-like protein 34.
XX
KW   Human; ankyrin-like protein 34; cytostatic; virucidal; immunomodulatory;
KW   antiinflammatory; haemostatic; gene therapy; malignant tumour;
KW   haemopathy; HIV infection; immunological disease; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200155194-A1.
XX
PD   02-AUG-2001.
XX
PF   21-JAN-2001; 2001WO-CN00085.
XX
PR   28-JAN-2000; 2000CN-0111595.
XX
PA   (BIOD-) BIODOOR GENE TECHNOLOGY LTD SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2001-483222/52.
DR   N-PSDB; AAH75702.
XX
PT   New human ankyrin-like protein 34 for diagnosing and treating malignant
PT   tumor, hemopathy, human immunodeficiency virus infection, immunological
PT   diseases and various inflammations  -
XX
PS   Claim 1; Page 31-32; 38pp; Chinese.
XX
CC   The present sequence is the protein sequence for human ankyrin-like
CC   protein 34. The ankyrin-like protein and its coding sequence are useful
CC   in the diagnosis and treatment of malignant tumour, haemopathy, HIV
CC   infection, immunological diseases and various inflammations.
XX
SQ   Sequence   313 AA;

  Query Match             46.3%;  Score 621.5;  DB 22;  Length 313;
  Best Local Similarity   60.6%;  Pred. No. 8.1e-55;
  Matches  126;  Conservative   26;  Mismatches   49;  Indels    7;  Gaps    2;

Qy      51 NPEPDASV------SSPQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELD 104
           :| |    |       |: :  | :| ||||||: ||||||  |   :|||:||||||||:
Db     104 SPSPGIQVRHVYTPSTTKHFSPIKQSTTLTNKHRGNEVSTTPLLANSLSVHQLAAQGEML 163

Qy     105 QLKEHLRKGDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLA 164
           |    : : :|::|  || |||||:||:| |:|  | |||: |||| :| | ||||||||
Db     164 YLATRIEQ-ENVINHTDEEGFTPLMWAAAHGQIAVVEFLLQNGADPQLLGKGRESALSLA 222

Qy     165 STGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGY 224
           : |||||| :||:  ||:| |||||||||||||| |||||||: ||  ||| | | ||||
Db     223 CSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLLESGADPTIETDSGY 282

Qy     225 TPMDLAVALGYRKVQQVIENHILKLFQS 252
           |||||||||| |||||:|:||| |:
Db     283 NSMDLAVALGYRSVQQVIESHLLKLLQN 310


RESULT 6
AAB94322
ID   AAB94322 standard; Protein; 313 AA.
XX
AC   AAB94322;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:14803.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 14803; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
```

```
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence   313 AA;

  Query Match             46.3%;  Score 621.5;  DB 22;  Length 313;
  Best Local Similarity   60.6%;  Pred. No. 8.1e-55;
  Matches  126;  Conservative   26;  Mismatches   49;  Indels    7;  Gaps    2;

Qy       51 NPEPDASV------SSPQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELD 104
              :| |   |      |: :  | :| |||||: ||||||  |   :|||:||||||||:
Db      104 SPSPGIQVRHVYTPSTTKHFSPIKQSTTLTNKHRGNEVSTTPLLANSLSVHQLAAQGEML 163

Qy      105 QLKEHLRKGDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLA 164
               |   : : :|::|  || |||||:||:| |:|  | |||: |||| :| | ||||||||
Db      164 YLATRIEQ-ENVINHTDEEGFTPLMWAAAHGQIAVVEFLLQNGADPQLLGKGRESALSLA 222

Qy      165 STGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGY 224
             : |||||| :||:  ||:| |||||||||||| |||||||: ||  ||| | | ||||
Db      223 CSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLLESGADPTIETDSGY 282

Qy      225 TPMDLAVALGYRKVQQVIENHILKLFQS 252
               |||||||||| ||||||:|:||| |:
Db      283 NSMDLAVALGYRSVQQVIESHLLKLLQN 310


RESULT 7
AAU20646
ID   AAU20646 standard; Protein; 263 AA.
XX
AC   AAU20646;
XX
DT   06-DEC-2001  (first entry)
XX
DE   Human secreted protein, Seq ID No 638.
XX
KW   Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW   rheumatoid arthritis; antiarteriosclerotic; cardiant; vascular;
KW   cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW   cytostatic; Alzheimer's disease; Parkinson's disease; human; cancer;
KW   multiple sclerosis; cancer; hyperproliferative disorder; infection;
KW   Gaucher's disease; neurological disease; cerebrovascular disorder;
KW   thrombosis; wound healing.
XX
OS   Homo sapiens.
XX
PN   WO200155326-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01347.
XX
PR   31-JAN-2000; 2000US-0179065.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-451931/48.
DR   N-PSDB; AAS33355.
XX
PT   New nucleic acids and polypeptides, useful for diagnosing, preventing
PT   or treating medical conditions -
XX
PS   Claim 11; SEQ ID No 638; 753pp; English.
XX
CC   The invention relates to novel isolated nucleic acid molecules (I)
CC   encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC   treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC   goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC   the prevention, treatment and diagnosis of diseases associated with
CC   inappropriate expression of secreted proteins. (I) and complementary
CC   sequences may also be used as DNA probes in diagnostic assays (e.g.
CC   polymerase chain reactions (PCR)) to detect and quantitate the presence
CC   of similar nucleic acid sequences in samples, and so which patients may
CC   be in need of restorative therapy. (II) may also be used as antigens in
CC   the production of antibodies and in assays to identify modulators
CC   (agonists and antagonists) of the expression and activity of the secreted
CC   proteins. The anti-(II) antibodies and antagonists may also be used to
CC   down regulate expression and activity of (II). The anti-(II) antibodies
CC   may also be used as diagnostic agents for detecting the presence of (II)
CC   in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC   disorders include for example: immune/autoimmune diseases (e.g. HIV
CC   (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC   and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC   melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC   Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC   Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC   cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC   angina and thrombosis), infections caused by bacteria, viruses and
CC   fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC   agonists, antagonists and antibodies can also be used to promote wound
CC   healing, maintain organs before transplantation, and support cell culture
CC   of primary tissues. AAU20342-AAU20666 represent human secreted protein
CC   amino acid sequences, and related sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification but was obtained in electronic format directly from WIPO
CC   at: ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   263 AA;

  Query Match             45.3%;  Score 607.5;  DB 22;  Length 263;
  Best Local Similarity   59.4%;  Pred. No. 1.7e-53;
  Matches  123;  Conservative   26;  Mismatches   51;  Indels    7;  Gaps    2;

Qy       51 NPEPDASV------SSPQAGSSLKHSTTLTNRQRGNEVSALPATLDSLSIHQLAAQGELD 104
              :| |   |      |: :  | :| |||||: ||||||  |   :|||:||||||||:
Db       36 SPSPGIQVRHVYTPSTTKHFSPIKQSTTLTNKHRGNEVSTTPLLANSLSVHQLAAQGEML 95

Qy      105 QLKEHLRKGDNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLA 164
               |   : : :|::|  || |||||:||:| |:|  | |||: |||| :| | ||||||||
Db       96 YLATRIEQ-ENVINHTDEEGFTPLMWAAAHGQIAVVEFLLQNGADPQLLGKGRESALSLA 154

Qy      165 STGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGY 224
             : |||||| :||:  ||:| |||||||||||| ||| |||: ||  ||| | | ||||
Db      155 CSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHXKCVKMLLESGADPTIETDSGY 214

Qy      225 TPMDLAVALGYRKVQQVIENHILKLFQ 251
               |||||||||| ||||||:|:|  |:
Db      215 NSMDLAVALGYRSVQQVIESHLLNCFK 241


RESULT 8
ABB50161
ID   ABB50161 standard; Protein; 152 AA.
XX
AC   ABB50161;
XX
DT   05-FEB-2002  (first entry)
XX
DE   Human transcription factor TRFX-12.
XX
KW   Human; transcription factor; TRFX; cell proliferative disease;
KW   autoimmune disease; inflammation; neurological disease;
```

KW developmental disorder; cancer; AIDS; infection; cytostatic; anti-HIV;
KW neuroprotective; antiinflammatory; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200172777-A2.
XX
PD 04-OCT-2001.
XX
PF 13-MAR-2001; 2001WO-US08117.
XX
PR 13-MAR-2000; 2000US-0188986.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Hillman JL, Baughn MR, Yue H, Lal P, Lu DAM, Patterson C;
PI Azimzai Y, Bandman O, Tang YT, Mathur P, Shah P, Au-Young J;
PI Reddy R;
XX
DR WPI; 2001-570896/64.
DR N-PSDB; ABA82985.
XX
PT Novel transcription factor polypeptides, used to treat diseases
PT associated with altered activity and expression of TRFX, and to screen
PT for agents capable of modulating its activity -
XX
PS Claim 1; Pages 151-152; 327pp; English.
XX
CC The present sequence is the protein sequence for a human transcription
CC factor. The transcription factor and its coding sequence are useful in
CC the diagnosis, treatment and prevention of diseases associated with
CC altered expression of the transcription factor e.g. cell proliferative,
CC autoimmune/inflammatory, neurological and developmental disorders. A
CC number of specific disorders/diseases are given in the specification,
CC including: arteriosclerosis, cirrhosis, hepatitis, cancers, AIDS,
CC allergies, anaemia, asthma, autoimmune thyroiditis, bronchitis, atopic
CC dermatitis, diabetes mellitus, emphysema, Goodpasture's syndrome, gout,
CC Grave's disease, multiple sclerosis, osteoarthritis, pancreatitis,
CC psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative
CC colitis, uveitis, Alzheimer's disease, Huntington's disease, Parkinson's
CC disease, stroke, and viral, bacterial, fungal and protozoal infections.
XX
SQ Sequence 152 AA;

Query Match 36.9%; Score 495; DB 22; Length 152;
Best Local Similarity 68.3%; Pred. No. 2.3e-42;
Matches 95; Conservative 16; Mismatches 28; Indels 0; Gaps 0;

```
Qy     114 DNLVNKPDERGFTPLIWASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIV 173
           :|::|  || |||||:||:| |:|  | |||: |||| :| | |||||||| : ||||||
Db      11 ENVINHTDEEGFTPLMWAAAHGQIAVVEFLLQNGADPQLLGKGRESALSLACSKGYTDIV 70

Qy     174 GLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVAL 233
            :||:  ||:| |||||||||||| |||||||: ||  ||| | | ||||  |||||||
Db      71 KMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLLESGADPTIETDSGYNSMDLAVAL 130

Qy     234 GYRKVQQVIENHILKLFQS 252
           ||| ||||||:|:||| |:
Db     131 GYRSVQQVIESHLLKLLQN 149
```

RESULT 9
AAG01584
ID AAG01584 standard; Protein; 84 AA.
XX
AC AAG01584;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein, SEQ ID NO: 5665.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-0200610.
XX
PR 26-FEB-1999; 99US-0122487.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-500381/45.
DR N-PSDB; AAC01590.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS Claim 13; SEQ ID 5665; 71pp + CD-ROM; English.
XX
CC The present sequence is a polypeptide encoded by one of a large number
CC of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs
CC were prepared from total human RNAs or polyA+ RNAs derived from 30
CC different tissues. EST sequences usually correspond mainly to the 3'
CC untranslated region (UTR) of the mRNA because they are often obtained
CC from oligo-dT primed cDNA libraries. Such ESTs are not well suited for
CC isolating cDNA sequences derived from the 5' ends of mRNAs and even in
CC those cases where longer cDNA sequences have been obtained, the full 5'
CC UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'
CC ends and can therefore be used to obtain full length cDNAs and genomic
CC DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and
CC chromosome mapping procedures. They are used to obtain upstream
CC regulatory sequences and to design expression and secretion vectors.
XX
SQ Sequence 84 AA;

Query Match 31.4%; Score 421.5; DB 21; Length 84;
Best Local Similarity 98.8%; Pred. No. 3e-35;
Matches 84; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

```
Qy       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSS 60

Qy      61 PQAGSSLKHSTTLTNRQRGNEVSAL 85
           || ||||||||||||||||||||||
Db      61 PQ-GSSLKHSTTLTNRQRGNEVSAL 84
```

RESULT 10
AAU20665
ID AAU20665 standard; Protein; 119 AA.
XX
AC AAU20665;
XX
DT 04-DEC-2001 (first entry)
XX
DE Human secreted protein, Seq ID No 657.
XX
KW Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW rheumatoid arthritis; antiarteriosclerotic; cardiant; vascular;
KW cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW cytostatic; Alzheimer's disease; Parkinson's disease; human; cancer;
KW multiple sclerosis; cancer; hyperproliferative disorder; infection;
KW Gaucher's disease; neurological disease; cerebrovascular disorder;
KW thrombosis; wound healing.
XX
OS Homo sapiens.
XX

PN WO200155326-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01347.
XX
PR 31-JAN-2000; 2000US-0179065.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451931/48.
DR N-PSDB; AAS33374.
XX
PT New nucleic acids and polypeptides, useful for diagnosing, preventing
PT or treating medical conditions -
XX
PS Claim 11; SEQ ID No 657; 753pp; English.
XX
CC The invention relates to novel isolated nucleic acid molecules (I)
CC encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC the prevention, treatment and diagnosis of diseases associated with
CC inappropriate expression of secreted proteins. (I) and complementary
CC sequences may also be used as DNA probes in diagnostic assays (e.g.
CC polymerase chain reactions (PCR)) to detect and quantitate the presence
CC of similar nucleic acid sequences in samples, and so which patients may
CC be in need of restorative therapy. (II) may also be used as antigens in
CC the production of antibodies and in assays to identify modulators
CC (agonists and antagonists) of the expression and activity of the secreted
CC proteins. The anti-(II) antibodies and antagonists may also be used to
CC down regulate expression and activity of (II). The anti-(II) antibodies
CC may also be used as diagnostic agents for detecting the presence of (II)
CC in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC disorders include for example: immune/autoimmune diseases (e.g. HIV
CC (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC angina and thrombosis), infections caused by bacteria, viruses and
CC fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC agonists, antagonists and antibodies can also be used to promote wound
CC healing, maintain organs before transplantation, and support cell culture
CC of primary tissues. AAU20342-AAU20666 represent human secreted protein
CC amino acid sequences, and related sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification but was obtained in electronic format directly from WIPO
CC at: ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 119 AA;

Query Match 29.3%; Score 393; DB 22; Length 119;
Best Local Similarity 72.6%; Pred. No. 4.1e-32;
Matches 77; Conservative 9; Mismatches 20; Indels 0; Gaps 0;

```
Qy    147 GADPHILAKERESALSLASTGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCV 206
          |||| :| | |||||||| : |||||| :||:  ||:| |||||||||||| |||||||
Db     11 GADPQLLGKGRESALSLACSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCV 70

Qy    207 EALLARGADLTTEADSGYTPMDLAVALGYRKVQQVIENHILKLFQS 252
          : ||  ||| | | ||||  |||||||||| ||||||:|:||| |:
Db     71 KMLLESGADPTIETDSGYNSMDLAVALGYRSVQQVIESHLLKLLQN 116
```

RESULT 11
AAU20558
ID AAU20558 standard; Protein; 105 AA.
XX
AC AAU20558;
XX
DT 04-DEC-2001 (first entry)
XX
DE Human secreted protein, Seq ID No 550.
XX
KW Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW rheumatoid arthritis; antiarteriosclerotic; cardiant; vascular;
KW cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW cytostatic; Alzheimer's disease; Parkinson's disease; human; cancer;
KW multiple sclerosis; cancer; hyperproliferative disorder; infection;
KW Gaucher's disease; neurological disease; cerebrovascular disorder;
KW thrombosis; wound healing.
XX
OS Homo sapiens.
XX
PN WO200155326-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01347.
XX
PR 31-JAN-2000; 2000US-0179065.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451931/48.
DR N-PSDB; AAS33267.
XX
PT New nucleic acids and polypeptides, useful for diagnosing, preventing
PT or treating medical conditions -
XX
PS Claim 11; SEQ ID No 550; 753pp; English.
XX
CC The invention relates to novel isolated nucleic acid molecules (I)
CC encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC the prevention, treatment and diagnosis of diseases associated with
CC inappropriate expression of secreted proteins. (I) and complementary
CC sequences may also be used as DNA probes in diagnostic assays (e.g.
CC polymerase chain reactions (PCR)) to detect and quantitate the presence
CC of similar nucleic acid sequences in samples, and so which patients may
CC be in need of restorative therapy. (II) may also be used as antigens in
CC the production of antibodies and in assays to identify modulators
CC (agonists and antagonists) of the expression and activity of the secreted
CC proteins. The anti-(II) antibodies and antagonists may also be used to
CC down regulate expression and activity of (II). The anti-(II) antibodies
CC may also be used as diagnostic agents for detecting the presence of (II)
CC in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC disorders include for example: immune/autoimmune diseases (e.g. HIV
CC (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC angina and thrombosis), infections caused by bacteria, viruses and
CC fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC agonists, antagonists and antibodies can also be used to promote wound
CC healing, maintain organs before transplantation, and support cell culture
CC of primary tissues. AAU20342-AAU20666 represent human secreted protein
CC amino acid sequences, and related sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification but was obtained in electronic format directly from WIPO
CC at: ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 105 AA;

Query Match 27.1%; Score 364; DB 22; Length 105;
Best Local Similarity 73.5%; Pred. No. 3.1e-29;
Matches 72; Conservative 8; Mismatches 18; Indels 0; Gaps 0;

```
Qy     155 KERESALSLASTGGYTDIVGLLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGA 214
           | |||||||| : |||||| :||:  ||:| |||||||||||| |||||||: ||  ||
Db       5 KGRESALSLACSKGYTDIVKMLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLLESGA 64

Qy     215 DLTTEADSGYTPMDLAVALGYRKVQQVIENHILKLFQS 252
           | | | |||| |||||||||| ||||||:|:||| |:
Db      65 DPTIETDSGYNSMDLAVALGYRSVQQVIESHLLKLLQN 102
```

RESULT 12
ABB97342
ID ABB97342 standard; Protein; 81 AA.
XX
AC ABB97342;
XX
DT 27-JUN-2002 (first entry)
XX
DE Novel human protein SEQ ID NO: 610.
XX
KW Human; antianaemic; vulnerary; antiinflammatory; immunomodulator;
KW antiinfertility; cerebroprotective; cytostatic; rheumatic; gene therapy;
KW neuroprotective; antiparkinsonian; protein therapy; EST;
KW expressed sequence tag.
XX
OS Homo sapiens.
XX
PN WO200222660-A2.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US26015.
XX
PR 11-SEP-2000; 2000US-0659671.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Drmanac RT;
XX
DR WPI; 2002-292408/33.
DR N-PSDB; ABN32528.
XX
PT An isolated polynucleotide for treating diseases associated with its
PT encoded polypeptide such as cancer and multiple sclerosis -
XX
PS Example 2; SEQ ID NO 610; 509pp; English.
XX
CC The present invention provides the protein and coding sequences of 444
CC novel human proteins. These were isolated from expressed sequences tags
CC (ESTs). They can be used to stimulate cell growth, to regulate
CC haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth
CC e.g. in burn treatment, to regulate the immune system e.g. to treat
CC multiple sclerosis, to regulate activin or inhibin e.g. to treat
CC infertility, to regulate haemostasis or thrombolysis e.g. to treat
CC stroke and cancer, to screen for drugs, to treat inflammatory conditions
CC e.g. rheumatoid arthritis, and to treat nervous system disorders e.g.
CC Parkinson's disease. The present sequence is a protein of the invention.
XX
SQ Sequence 81 AA;

Query Match 22.3%; Score 299; DB 23; Length 81;
Best Local Similarity 73.1%; Pred. No. 9.3e-23;
Matches 57; Conservative 7; Mismatches 14; Indels 0; Gaps 0;

```
Qy     175 LLLERDVDINIYDWNGGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALG 234
           :||:  ||:| |||||||||||| |||||||: ||  ||| | | ||||  ||||||||
Db       1 MLLDCGVDVNEYDWNGGTPLLYAVHGNHVKCVKMLLESGADPTIETDSGYNSMDLAVALG 60

Qy     235 YRKVQQVIENHILKLFQS 252
           || ||||||:|:||| |:
Db      61 YRSVQQVIESHLLKLLQN 78
```

RESULT 13
ABB61859
ID ABB61859 standard; Protein; 234 AA.
XX
AC ABB61859;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 12369.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL05962.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 12369; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 234 AA;

Query Match 20.4%; Score 274; DB 22; Length 234;
Best Local Similarity 33.8%; Pred. No. 1.6e-19;
Matches 80; Conservative 37; Mismatches 96; Indels 24; Gaps 6;

```
Qy      13 TQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEPVNPEPDASVSSPQAGSSLKHSTT 72
           | || |:     :| |  :|  |  |: :       |  |:                ||
Db       7 TIQTNAN---SDDDEGVRSAPTSMLVLDAKRKSAFLPYRPQ---------------STV 47

Qy      73 LTNRQRGN-EVSALPATLDSLSIHQLAAQGEL--DQLKEHLRKGDNLVNKPDERGFTPLI 129
           ||| |||| | :  |  : ||| |: | |||:  :|:     :  |:  | |  ||| |
Db      48 LTNLQRGNTEATFCPVEV-SLSPHERAGQGEITEEQVAAERARQQNIDYK-DAHGFTALH 105

Qy     130 WASAFGEIETVRFLLEWGADPHILAKERESALSLASTGGYTDIVGLLLERDVDINIYDWN 189
           ||:::|:: :|: |:  ||: : :| :  | | ||: ||: :||  |||   |    |
Db     106 WAASYGQLVSVQLLVAAGANVNTMAPDLISPLLLAAAGGHNEIVRFLLEHGADSGHMDIV 165

Qy     190 GGTPLLYAVRGNHVKCVEALLARGADLTTEADSGYTPMDLAVALGYRKVQQVIENHI 246
           | | |:||  |||      |||:  ||:   : | |   |||  |    | ::| ::
Db     166 GNTALMYAAAGNHPHTCNELLAKDLDLSATNEDGDTAYSLAVEHGAHLAQALLEQYM 222
```

RESULT 14
ABB43550
ID ABB43550 standard; Peptide; 49 AA.
XX
AC ABB43550;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #11056 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human fetal liver -
XX
PS Claim 27; SEQ ID NO 36185; 639pp + sequence listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for predicting,
CC measuring and displaying gene expression in samples derived from human
CC fetal liver. The present sequence is a peptide encoded by a single exon
CC nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 49 AA;

Query Match 19.2%; Score 257; DB 22; Length 49;
Best Local Similarity 100.0%; Pred. No. 8.5e-19;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEP 49
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEP 49

RESULT 15
AAM21225
ID AAM21225 standard; Protein; 49 AA.
XX
AC AAM21225;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #7659 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00670.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human cervical epithelial cells -
XX
PS Claim 27; SEQ ID No 26051; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 49 AA;

Query Match 19.2%; Score 257; DB 22; Length 49;
Best Local Similarity 100.0%; Pred. No. 8.5e-19;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEP 49
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MELTQPAEDLIQTQQTPASELGDPEDPGEEAADGSDTVVLSLFPCTPEP 49

Search completed: March 17, 2003, 16:39:38
Job time : 42 secs